A proteomics approach for the development of sarcoma biomarkers

Abstract

Sarcomas are rare and clinically diverse malignancies, and treatment optimization requires the development of suitable biomarkers. In earlier research employing proteomics analysis, we identified peroxiredoxin 2 as a biomarker of osteosarcoma (OS) that can predict response to neoadjuvant chemotherapy and verified its functional significance in the resistance of OS cells to chemotherapeutic drugs. In addition, in gastrointestinal stromal tumor (GIST), we identified pfetin as a prognostic biomarker and validated its prognostic utility in multi-institutional studies by immunohistochemistry. Here, we present an overview of our progress in sarcoma proteomics and discuss future perspectives.

Keywords

• Sarcoma
• Osteosarcoma
• Gastrointestinal stromal tumor
• Peroxiredoxin 2
• Pfetin
• Two-dimensional difference gel electrophoresis